Risk of Status Epilepticus in Southern Europe

Risk of Status Epilepticus in Southern Europe

Published: European Neurology - Volume 3 Issue 2
dots

The epidemiological features of status epilepticus (SE) are in the course of definition.1 In northern and central Europe, an incidence of 10.3 and 17.1/100,000/year and a mortality rate of 7.6 and 9.3% have been reported, respectively.2,3 In southern Europe, an incidence of 10.7 and 11.6/100,000/year and a mortality rate of 7 and 39% have been estimated.1,4 In the US, a higher incidence of 18.3 and 41/100.000/year5,6 and a mortality rate of 19 and 22%6,7 have been observed. Given the limited data available in southern Europe,1,4 in 2003 we carried out an intensive survey of multiple sources of case material of SE in the Health District (HD) of Ferrara (Fe) in Italy.8

Methods
The study population was the resident population (in 2003, an average of 148,128 inhabitants; 46.9% men) of the HD of Fe, a well-defined area of 724km2 in the province of Ferrara, Italy, which is the primary service area of the University Hospital (UH) of Fe (the only general hospital in this HD). The study period was from 1 January 2003 to 31 December 2003. In the HD of Fe, neurological patients are routinely referred to the UH of Fe,9–11 where an on-call neurologist is available 24 hours a day, seven days a week. The HD territorial emergency service protocol for SE management recommends administering benzodiazepines intravenously (IV) and moving the patient as soon as possible to the UH emergency room. The purpose of the study was to identify SE cases in the study population in 2003 through an intensive survey of multiple sources of cases. All hospital ICD-9 discharge codes in 2003 concerning epilepsy in all positions were abstracted, and the clinical files were obtained from each hospital ward. Other sources were the UH electroencephalography (EEG) and paediatric EEG services archives. Further sources were the emergency room unit and the territorial emergency service computerised archives. The neurologists, the physicians in the paediatric neurological service and the physicians in the emergency room unit and the intensive care units of the UH of Fe were interviewed.

SE was defined as a single seizure lasting for more than 30 minutes or repeated seizures lasting for a period of more than 30 minutes without intervening recovery between seizures.12 Charts of any possible SE case in 2003 selected through the above sources were carefully reviewed to identify those with SE and to classify SE by seizure type, duration and aetiology. SE seizure type was classified as: generalised from onset (no indication of anatomical localisation and no clinical evidence of focal onset), with the subgroups convulsive (tonic-clonic, tonic, clonic), non-convulsive (absence status) and myoclonic; partial, without generalisation, with the subgroups simple (no consciousness impairment) and complex (consciousness impairment); secondarily generalised; and unclassified.12 The physicians involved in the management of SE patients were interviewed. Only the first SE episode was taken into account.3,5 Each SE case was reviewed according to the Hauser criteria13 to determine whether it was acute symptomatic (in close association – within a week – with an acute brain insult) or unprovoked (no association with an acute brain insult); the latter cases were further categorised as progressive symptomatic (in association with a non-static progressive brain lesion), remote symptomatic (in association with a prior brain insult resulting in a static brain lesion; time between SE and the prior brain insult >1 week) or idiopathic/cryptogenic (no acute precipitating factor and no brain lesion), concerning SE of no clear aetiology – idiopathic was reserved for certain partial or generalised epileptic syndromes with particular clinical and EEG characteristics, while cryptogenic referred to cases where no factor associated with increased risk of seizures was identified. The only case of febrile SE (a special class of acute symptomatic SE occurring during a febrile illness among children in the absence of another acute symptomatic cause, such as central nervous system [CNS] infection)2,5 was not excluded from the statistical analysis.

References:
  1. Vignatelli L, Tonon C, D’Alessandro R, on behalf of the Bologna Group for the Study of Status Epilepticus, Incidence and Shortterm Prognosis of Status Epilepticus in Adults in Bologna, Italy, Epilepsia, 2003;44(7):964–8.
  2. Coeytaux A, Jallon P, Galobardes B, Morabia A, Incidence of status epilepticus in French – speaking Switzerland (EPISTAR), Neurology, 2000;55:693–7.
  3. Knake S, Rosenow F, Vescovi M, et al., for the Status Epilepticus Study Group Hessen (SESGH), Incidence of Status Eepilepticus in Adults in Germany: A Prospective, Population- Based Study, Epilepsia, 2001;42(6):714–18.
  4. Vignatelli L, Rinaldi R, Galeotti M, et al., Epidemiology of status epilepticus in a rural area of northern Italy: a 2-year populationbased study, Eur J Neurol, 2005;12(11):897–902.
  5. Hesdorffer DC, Logroscino G, Cascino G, et al., Incidence of status epilepticus in Rochester, Minnesota, 1965–1984, Neurology, 1998;50:735–41.
  6. DeLorenzo J, Hauser WA, Towne AR, et al., A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia, Neurology, 1996;46:1029–35.
  7. Logroscino G, Hesdorffer DC, Cascino G, et al., Short term mortality after a first episode of status epilepticus, Epilepsia, 1997;38(12):1344–9.
  8. Govoni V, Fallica E, Monetti VC, et al., Incidence and shortterm prognosis of status epilepticus in the Health District of Ferrara, Italy, in 2003, Neurol Sci, 2005;26(Suppl.):139–40.
  9. Govoni V, Granieri E, Capone J,et al., Amyotrophic Lateral Sclerosis in the Local Health District of Ferrara, Italy, 1964–1998, Neuroepidemiology, 2003;22:229–34.
  10. Govoni V, Granieri E, Manconi M, et al., Is there a decrease in Guillain-Barré syndrome after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy, J Neurol Sci, 2003;216(1):99–103.
  11. Govoni V, Granieri E, Fallica E, Casetta I, Amyotrophic lateral sclerosis, rural environment and agricultural work in the Local Health District of Ferrara, Italy, in the years 1964–1998, J Neurol, 2005;252:1322–7.
  12. Commission on Epidemiology and Prognosis, International League against Epilepsy, Guidelines for Epidemiologic studies on Epilepsy, Epilepsia, 1993;34:592–6.
  13. Hauser WA, Annegers JF, Kurland LT, Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984, Epilepsia, 1993;34:45–68.
  14. Waterhause J, Muir C, Shanmungaratham K, Powel J, Cancer incidence in five continents, IARC Sci Publ, 1982;4:673.
  15. Schoenberg BS, Calculating confidence intervals for rates and ratios, Neuroepidemiology, 1983;2:257–65.
  16. Hibberd PL, Use and Misure of Statistics for Epidemiological Studies in Multpile Sclerosis, Ann Neurol, 1994;36(S2): S218–S230.
  17. Towne AR, Waterhouse EJ, Boggs JG, et al., Prevalence of nonconvulsive status epilepticus in comatose patients, Neurology, 2000;54(2):340–45.
  18. Treinman DM, Meyers PD, Walton NY, et al., A comparison of four treatment for generalized convulsive status epilepticus, N Engl J Med, 1998;339(12):792–8.
  19. Leppik IE, Derivan AT, Homan RW, et al., Double-blind study of lorazepam and diazepam in status epilepticus, JAMA ,1983; 249(11):1452–4.

Copyright® 2012 Touch Group PLC. All rights reserved.
Touch Neurology is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.